Doctors often gloss over a key questionfor assessing a person's risk for coronary heart disease, according to a new study: What is the patient's family history of cardiovascular illness?
And rather than suggesting it was folly for AstraZeneca to support this study, they should receive public praise and encouragement for taking a risk and putting the key question about the marginal benefit of their product on the table.